Can Ozempic Treat Fatty Liver Disease? What the Evidence Shows in 2026

The definitive evidence comes from the ESSENCE trial — a phase 3, randomised controlled clinical trial involving 800 participants across 37 countries over 72 weeks, published in the New England Journal of Medicine in May 2025.

The ESSENCE trial used semaglutide at 2.4mg weekly — the Wegovy dose, not the standard Ozempic diabetes dose of 1mg — in patients with biopsy-confirmed MASH and liver fibrosis at stages F2 or F3.

The results confirmed that semaglutide can halt and even reverse fatty liver disease in a significant proportion of patients. Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring — 63%, compared with 34% of those taking a placebo.

Beyond MASH resolution, 37% of patients on semaglutide showed improvement in fibrosis stage by at least one level — meaning actual reversal of established liver scarring — compared to 22.4% on placebo. This is clinically significant: it demonstrates semaglutide does not merely halt progression but can actively repair damaged liver tissue in many patients.

Unlike resmetirom, which works directly on the liver, semaglutide has a broader effect on the body as a result of its effectiveness in treating type 2 diabetes and obesity. For many people, liver disease is driven by obesity or type 2 diabetes. Research shows that treating these underlying conditions with semaglutide reduces fat, inflammation, and scarring in the liver simultaneously.

The liver benefits of semaglutide appear to come through several pathways simultaneously. Weight loss reduces the delivery of free fatty acids to the liver, directly decreasing fat accumulation. But this is not the full story.

Pathway 1 — Weight loss and fat mobilisation: As body weight decreases on semaglutide, visceral fat — the fat most closely associated with MASLD — is preferentially reduced. This decreases the influx of fatty acids to the liver.

Pathway 2 — Insulin sensitivity improvement: Insulin resistance drives fat accumulation in the liver by increasing fatty acid delivery from adipose tissue and stimulating hepatic fat synthesis. As semaglutide improves insulin sensitivity, this metabolic stimulus is reduced.

Pathway 3 — Direct hepatic action: Secondary analyses of the ESSENCE trial presented at AASLD 2025 demonstrated liver benefits that were not fully explained by weight loss alone — even after accounting for the degree of weight reduction, semaglutide showed superior liver outcomes compared to what weight loss alone would predict. GLP-1 receptors expressed on liver sinusoidal endothelial cells appear to mediate anti-inflammatory and anti-fibrotic effects directly.

The ESSENCE trial used semaglutide 2.4mg weekly — the Wegovy dose. Most Australians taking Ozempic for type 2 diabetes are on a lower dose, up to 1mg weekly.

Does the standard Ozempic dose also treat fatty liver disease?

The clinical evidence suggests yes — at a lower magnitude. Real-world observational studies and earlier clinical trials using lower semaglutide doses have consistently shown liver fat reduction, liver enzyme improvement, and reduced progression of MASLD compared to other diabetes medications. A 2023 meta-analysis found that GLP-1 receptor agonists as a class significantly reduced liver fat content, liver enzymes, and inflammatory markers compared to placebo across multiple trials.

The liver benefits of semaglutide are dose-dependent. The higher the dose, the greater the hepatic effect. But patients on the standard Ozempic diabetes dose are not receiving zero liver benefit — they are receiving a meaningful hepatic benefit that may be insufficient to achieve MASH resolution in more advanced disease, but is real and clinically relevant for patients with early MASLD.

For patients with established MASH at F2–F3 fibrosis who need the most effective treatment, the appropriate prescription is Wegovy at 2.4mg under the new TGA indication. For patients managing type 2 diabetes with comorbid MASLD, Ozempic provides meaningful but lower-magnitude liver benefit.

In April 2026, the TGA granted provisional approval for Wegovy (semaglutide 2.4mg) for the treatment of adults with non-cirrhotic MASH with moderate to advanced liver fibrosis (stages F2–F3). This was the first GLP-1 medication approved in Australia specifically for liver disease treatment.

The approval is provisional — Novo Nordisk must provide confirmatory long-term outcomes data. However, it represents a formal recognition that semaglutide is a disease-modifying treatment for MASH, not merely a beneficial side effect of weight loss.

For Australian patients, this means:

• Patients with confirmed MASH at F2–F3 fibrosis can now be prescribed Wegovy specifically for liver treatment by a hepatologist or gastroenterologist
• The treatment has TGA-sanctioned regulatory standing for this indication
• Monitoring protocols and prescribing guidance are now formally established

Understanding what Ozempic or Wegovy can realistically achieve for liver disease at different time points helps patients set appropriate expectations.

Weeks 1–12 (rapid weight loss phase): Liver fat content begins to decrease as body weight reduces. Liver enzymes (ALT, AST) may initially fluctuate — some transient elevation can occur during rapid fat mobilisation before stabilising and improving.

Months 3–6: Significant liver fat reduction confirmed on elastography or CAP score. Liver enzymes typically normalise or significantly improve. Patients with MASLD begin to show measurable improvements in liver stiffness (kPa) on follow-up elastography.

Months 6–12: In patients with MASH, histological improvement may be occurring — inflammation reducing, early fibrosis beginning to resolve. This is not directly visible without biopsy or detailed elastography follow-up, but improving liver enzymes and decreasing liver stiffness suggest it.

Months 12–18: The magnitude of MASH resolution seen in the ESSENCE trial (62.9% resolution at 72 weeks) suggests significant benefit is accumulating through this period. Patients with F2–F3 fibrosis who respond well may begin to show fibrosis stage improvement on repeat elastography.

Important caveat: Fibrosis improvement did not reach statistical significance in the phase 2 trial, meaning semaglutide resolved the inflammation component of MASH more reliably than it reversed existing scarring. Reversing established fibrosis requires more time and may require higher degrees of weight loss than 72 weeks of treatment produced. The phase 3 ESSENCE data shows fibrosis improvement at higher rates than phase 2, but this remains a realistic expectation rather than a certainty.

The most practical way to assess whether semaglutide is improving your liver health is through liver elastography — the same non-invasive scan used for initial assessment.

A repeat liver elastography 12 months after starting Ozempic or Wegovy can provide direct evidence of whether liver stiffness (kPa) has decreased, CAP score (liver fat) has decreased, and the overall fibrosis stage has improved.

Combined with routine liver function tests (ALT, AST, GGT) showing improving trends, this gives a comprehensive picture of liver treatment response.

Find a liver elastography clinic near you →